2-Ethyl-4-(methylamino)butan-1-ol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Ethyl-4-(methylamino)butan-1-ol
• 英文别名: 2-ethyl-4-(methylamino)butan-1-ol
• 化学式: C₇H₁₇NO
• 分子量: 131.22
• InChiKey: SEQRMDBRYIGQDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
  申请人：Kirin Pharma Kabushiki Kaisha

  公开号：EP2088141A2

  公开（公告）日：2009-08-12

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X = CH or N; Z = O or S; L = O or S; M = CR10R11, wherein R10 and E11 = H, alkyl, or alkoxy, NR12 wherein R12 = H or alkyl; R1, R2, and R3 = H or optionally substituted alkoxy; R4 = H; R5-8 = H, halogen, alkoxy or the like; and R9 = alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T = O, S, or NH; R14 = an optionally substituted carbocyclic or heterocyclic ring; and R15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 = H, optionally substituted alkyl, or an optionally substituted carbocyclic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目的是提供具有强效抗肿瘤活性的化合物。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X = CH 或 N；Z = O 或 S；L = O 或 S；M = CR10R11，其中 R10 和 E11 = H、烷基或烷氧基，NR12，其中 R12 = H 或烷基；R1、R2 和 R3 = H 或任选取代的烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；R9 = 任选被 -R14、-T-R15 或 -NR16R17 取代的烷基，其中 T = O、S 或 NH；R14 = 任选取代的碳环或杂环；以及 R15-17 = 烷基或任选取代的碳环或杂环，或 -NR18R19 其中 R18 和 R19 = H、任选取代的烷基或任选取代的碳环或杂环，或任选取代的碳环或杂环。